Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

"CONFLICT OF INTEREST Dr. Myers is employed by and owns stock in Gilead. Dr. Afdhal advises Gilead and Echosens. Dr. Anstee consults for, is on the speakers’ bureau for, has active research collaborations with, and received grants from Allergan/Tobira. He consults for, has active research collaborations with, and received grants from AstraZeneca, Novartis, and Pfizer. He consults for, is on the speakers’ bureau for, and has active research collaborations with Bristol‐Myers Squibb and Genfit. He consults for and is on the speakers’ bureau for Abbott and Gilead. He consults for and has active research collaborations with Eli Lilly, HistoIndex, Intercept, and Novo Nordisk. He has active research collaborations with and received grants from AbbVie, GlaxoSmithKline, and Glympse Bio. He consults for 89Bio, Acuitas, Altimmune, Axcella, Blade, BNN Cardio, Celgene, Cirius, CymaBay, EcoR1, E3Bio, Galmed, Genentech, Grunthal, Indalo, Imperial Innovations, Inventiva, IQVIA, Janssen, Madrigal, Medimmune, Metacrine, NewGene, NGMBio, North Sea, Poxel, ProSciento, Raptor, Servier, Terns, and Viking. He has active research collaborations with Antaros, Boehringer Ingelheim, Echosens, Ellegaard Gottingen Minipigs AS, Exalenz, iXscient, Nordic Bioscience, One Way Liver Genomics, Perspectum, Resoundant, Sanofi‐Aventis, SomaLogic, and Takeda. He is on the speakers’ bureau for Clinical Care Options, Falk, Fishawack, Integritas, Kenes, and MedScape. He received grants from Vertex. He received royalties from Elsevier. Dr. Sanyal consults and received grants from Conatus, Gilead, Mallinckrodt, Immuron, Boehringer Ingelheim, Novartis, Bristol‐Myers Squibb, Merck, Eli Lilly, Novo Nordisk, Fractyl, Siemens, Madrigal, Inventiva, and Covance. He consults for and owns stock in Genfit. He consults for Intercept, Pfizer, Salix, Galectin, Hemoshear, Terns, Albireo, Sanofi, Janssen, Takeda, NorthSea, AMRA, Perspectum, Poxel, 89 Bio, AstraZeneca, NGM, Amgen, Regeneron, Genentech, Roche, Prosciento, Histoindex, Path AI, and Biocellvia. He received grants from Echosens‐Sandhill, Owl, and Second Genome. He owns stock in Exalenz, Sanyal Bio, Durect, Indalo, Tiziana, and Rivus. He received royalties from Elsevier and UptoDate. Dr. Trauner advises for, is on the speakers’ bureau for, and received grants from Gilead, Intercept, and MSD. He advises and received grants from Falk and Albireo. He advises BiomX, Boehringer Ingelheim, Genfit, Janssen, Novartis, Phenex, Regulus, and Shire. He is on the speakers’ bureau for Falk Foundation. He received grants from AbbVie, Alnylam, Cymabay, Takeda, and UltraGenyx. Dr. Lawitz received grants from 89Bio, Akero, Alnylam, Amgen, AstraZeneca, Axcella, Boehringer Ingelheim, Bristol‐Myers Squibb, Cymabay, CytoDyn, Durect, Eli Lilly, Enanta, Galectin, Galmed, Genentech, Gilead, Hanmi, Intercept, Inventiva, Janssen, Laboratory for Advanced Medicine, Madrigal, Merck, Metacrine, NGM, NorthSea, Novartis, Novo Nordisk, Pfizer, Poxel, Roche, Sagimet, Synlogic, Terns, Valeant, Viking, and Zydus. Dr. Abdelmalek received grants from Gilead. Dr. Ding is employed by and owns stock in Gilead. Dr. Jia is employed by and owns stock in Gilead. Dr. Huss is employed by and owns stock in Gilead. Dr. Chung is employed by and owns stock in Gilead. Dr. Wong consults for and received grants from Gilead. He consults for 3V‐Bio, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Inventiva, Merck, Novartis, Novo Nordisk, Pfizer, ProSciento, Sagimet, TARGET, and Terns. He is cofounder of Illuminatio Medical Technology Limited. Dr. Muir consults for and received grants from Gilead. He received grants from Cymabay. Dr. Bosch consults for Gilead and Actelion. Dr. Younossi consults for Gilead, Intercept, Novo Nordisk, Siemens, and Terns. Dr. Harrison consults for, advises, received grants from, and owns stock in Akero, Galectin, Genfit, Hepion, Metacrine, NGM, and NorthSea. He consults for, advises, and received grants from Axcella, Civi, CymaBay, Gilead, High Tide, Intercept, Madrigal, Novartis, Novo Nordisk, Poxel, and Sagimet. He consults for, advises, and owns stock in HistoIndex and Sonic Incytes. He consults for and advises Altimmune, Echosens, Foresite, Medpace, Prometic, Ridgeline, and Terns. He consults for and received grants from Enyo and Viking. He advises and received grants from Galmed. He advises and owns stock in Chronwell and PathAI. He received grants from and owns stock in Cirius. He consults for AgomAB, Alentis, Alimentiv, Boston Pharmaceuticals, B Riley, BVF, Canfite, Corcept, Fibronostics, Fortress, Inipharm, Ionis, Kowa, Microba, Nutrasource, and Piper Sandler. He advises 89Bio, Arrowhead, Indalo, and Theratechnologies."

"Funding information"